Alveolar rhabdomyosarcoma with massive disseminated intravascular coagulopathy treated with systemic chemotherapy

Article information

Abstract

Introduction

Disseminated intravascular coagulation (DIC) is a systemic thrombohemorrhagic disorder with variable pathophysiology. The underlying diseases causing DIC include obstetric accidents, intravascular hemolysis, septicemia, viremia, burns, trauma, acute liver disease, and malignant disease1). There is a causal relationship between DIC and the presence of malignancy2). The incidence of DIC was reported on 7% of the patients with solid tumor and 15%-20% of the patients with acute leukemia34). DIC in pediatric solid tumor has been reported with disseminated neuroblastoma, nephroblastoma, infantile fibrosarcoma, and multi-system Langerhans cell histiocytosis5). The pediatric patients with rhabdomyosarcoma presenting with DIC at diagnosis are rare and are mainly seen with the widespread alveolar rhabdomyosarcoma metastatic to bone marrow (BM)3). Clinically, DIC in cancer is less fulminant than the types of DIC seen in sepsis and trauma. Also, chronic and systemic activation of coagulation can progress subclinically, and this progression may lead to exhaustion of coagulation factors and platelets. Therefore, bleeding may be the first clinical symptom of DIC in a patient with cancer2).

Here, we describe an unusual case with acute bleeding and DIC, which were severe and very difficult to control, with the presenting manifestation of alveolar rhabdomyosarcoma metastatic to BM. Early administration of chemotherapy and vigorous supportive care could control the massive bleeding and DIC.

Case report

A 13-year-old boy was admitted in January 2011, due to an uncontrolled bleeding at the operation site of the right thenar muscle. The swelling of the right thenar muscle developed after a fall on August 2010 (Fig. 1A, B). However, no treatment was given under the impression that the swelling was a hematoma. After showing no improvement for over 5 months, excision of this lesion was attempted at a private orthopedic surgery clinic. Before marginal excision, the patient had no history of bleeding tendency and normal coagulation screening tests. He underwent two additional operations at different hospitals for the control of bleeding, but the bleeding at the operation site continued.

Fig. 1

Findings at initial presentation. (A, B) Magnetic resonance imaging revealed a 5×3.6×5-cm well-defined mass in the plantar aspect of the right thenar muscle (arrows). (A) A T1-weighted image with iso-signal intensity. (B) A T2-weighted image with heterogeneous high signal intensity. (C) At admission, bleeding at the site of the previous operation continued. (D) ¹⁸Fluoro-2-deoxyglucose-positron emission tomography revealed metastatic lymphadenopathy (maximum standardized uptake value [SUVmax], 5.3) in the right axillary space as well as postoperative inflammatory changes (SUVmax, 2.7) in the right thenar muscle (arrows). (E) Bone marrow smear showed small round blue cells, suggesting a nonhematopoietic malignancy (H&E, ×400).

When a pathologic finding of the mass suggested a diagnosis of malignancy, he was transferred to our hospital for further management. At the admission, the patient's general state was poor with signs of pallor, weakness, bruising at the intravenous site, and purpura on the operation site over the right thenar muscle with continuous bleeding (Fig. 1C). In the physical examination, there was a 2×2 cm-sized lymph node (LN) in the right axillary area and 1 cm-sized hepatosplenomegaly. Laboratory tests revealed markedly decreased platelet and hemoglobin levels and features suggestive of DIC (white blood cell, 9,900 /µL; hemoglobin, 4.8 g/dL; platelets, 28,000 /µL; prothrombin time, 1.47 international normalized ratio; activated partial thromboplastin time, 45.4 sec; fibrinogen, 87 mg/dL; fibrin/fibrinogen degeneration product, 656.4 µg/mL; and D-dimer, 16.17 mg/L). The coagulation factors II, VII, IX, fibrinogen, and von willebrand factor were all normal. The factors V and VIII were 30% (normal, 60%-140%) and 40% (normal, 50%-150%), respectively. 18-Fluoro-2-deoxy-D-glucose positron emission tomography scan showed hypermetabolic lesions (maximum standardized uptake value [SUVmax], 2.7) along the rim of a previous mass in the right thenar muscle and conglomerated hypermetabolic lesions (SUVmax, 5.3) in the right axillary space. It suggested post-operative inflammation in the right thenar muscle and metastatic lymphadenopathy in the right axillary space (Fig. 1D).

On the 3rd hospital day (HD), despite of the repeated blood product transfusions, the massive bleeding from the operation site and the intravenous access site worsened, and a gross hematuria developed. On the 4th HD, the pathologic findings of the mass were reported as alveolar rhabdomyosarcoma with positive immnunohistochemical stains of myognesin, desmin, and MyoD and with negative resection margin. The patient was transferred to the intensive care unit, and chemotherapy consisting of vincristine, doxorubicin, and cyclophosphamide (VAC) was administered. Also, repeated transfusions, synthetic protease inhibitor, and substitution of antithrombin-III were administered.

On the 10th HD, a massive epistaxis led to hematemesis of approximately 1.5 L of blood, and it required transfusions of 4 units of red blood cells (RBCs), 9 units of platelet concentrates (PCs), 1 unit of fresh frozen plasma (FFP), and 8 units of cryoprecipitate, with two times of cauterization. Two weeks after the chemotherapy was started, the laboratory findings of DIC showed improvement (Fig. 2), so a BM section biopsy and an axillary LN biopsy were performed. The histologic finding of BM (Fig. 1E) and axillary LN revealed involvement of rhabdomyosarcoma.

Fig. 2

Clinical course of the patient. After 2 weeks of chemotherapy and transfusion of a total of 311 units (26 units of red blood cell [RBC], 26 units of fresh frozen plasma [FFP], 74 units of platelet concentrate [PC], 17 units of platelet apheresis [PA], and 168 units of cryoprecipitate), the results of the coagulation test improved. On the 28th day after hospital admission, the patient was discharged. VAC, vincristine/doxorubicin/cyclophosphamide; V, vincristine; FDP, fibrin/fibrinogen degeneration product.

During the initial 20 days of admission, the patient received total blood transfusions of 311 units (26 units of RBC, 26 units of FFP, 74 units of PC, 17 units of single donor platelets, and 168 units of cryoprecipitate) for the control of the DIC and bleeding. On the 28th HD or three weeks after the start of chemotherapy, the patient was discharged.

The patient received a combination chemotherapy consisting of VAC every 3 weeks. At 9th week after the start of chemotherapy, the size of right axillary LN decreased from 3.6 cm to 2.1 cm. At 21st week after the start of chemotherapy, the BM showed disappearance of rhabodyosarcoma and negative immunostaining for desmin or myogenin. For the planned high-dose chemotherapy with autologous peripheral blood stem cell (APBSC) transplantation, two rounds of APBSC collections were performed. Unfortunately, however, at the 27th week of chemotherapy, the patient was found to have a nodule in the right forearm that was increasing in size for over 2 weeks, and the biopsy revealed it as an alveolar rhabdomyosarcoma. Despite of the salvage chemotherapy consisting of ifosfamide, carboplatin, etoposide, and palliative radiation therapy (right axilla, arm, thenar muscle, and liver, 36 Gy), the patient died 5 months later from the disease progression to the liver and the brain.

Discussion

The solid malignancies are rare causes of DIC, and the mechanism is unclear. Recent studies show that the solid tumors express different procoagulant molecules including tissue factor (TF), which binds to factor VII(a) to activate the factors IX and X, and to the cancer procoagulant, which is a cysteine protease with factor X-activating properties. Alternatively, most tumors induce a hypofibrinolytic state, due to high levels of fibrinolytic inhibitor such as plasminogen activator inhibitor type 1. Virtually, all pathways that lead to the occurrence of DIC are driven by proinflammatory cytokines, such as interleukin-6, interleukin-1β, interleukin-8, and tumor necrosis factor-α2).

The pediatric patients with rhabdomyosarcoma complicated with DIC at diagnosis are rare. These cases were found in the review5) of 13 cases, published from 1978 to 2010. Out of 11 patients with the involvement of BM, 10 cases in which the patients have recovered from the DIC received multiagent chemotherapy, and the recovery time from the DIC varied from 6 days to after 3 cycles of chemotherapy. Multivariate analysis revealed that the older age, male sex, primary tumor necrosis, and advanced tumor stage are the risk factors for DIC3).

The prognosis of alveolar rhabdomyosarcoma stage IV with the involvement of BM is very poor, especially in the cases complicated by massive DIC5). It is very important to administer chemotherapy early, with the aim of diminishing tumor-triggered procoagulant activity. There is a dilemma associated with this practice, because cytotoxic agents may aggravate DIC and may also suppress the BM. However, in an inoperable situation, administration of multidrug chemotherapy revealed to have an immediate beneficial effect, even if a measurable antitumor effect is not observed6). In the case reported here, despite of the continuous bleeding at the postoperative site, administration of VAC chemotherapy at 4th HD was undertaken and the DIC showed signs of improvement after the 2nd week of chemotherapy.

In the cancer patients complicated with DIC, once the treatment directed at the primary disorder is initiated, the additional supportive therapy may be required in order to correct the coagulation abnormalities. Although the low levels of platelet and coagulation factors may increase the risk of bleeding, the plasma or platelet substitution therapy is not indicated on the basis of the laboratory findings alone, unless an active bleeding is present or the invasive procedures are required7). In our patient, the massive bleeding required as many as 311 units of blood component replacement (26 units of RBC, 26 units of FFP, 74 units of PC, 17 units of single donor platelets, and 168 units of cryoprecipitate).

Based on the concept that DIC is characterized by systemic activation of coagulation, anticoagulant therapy may be a principle approach in therapy. However, the safety and efficacy of this strategy in malignancy-associated DIC have never been studied in proper clinical settings2). According to an experimental study, heparin therapy showed hopeful results in inhibiting the activation of coagulation in DIC8). In the cases with obvious thromboembolic disease or where fibrin deposition predominates, heparin therapy could be considered. However, our patient did not receive heparin therapy and only received repeated transfusions, synthetic protease inhibitor, and substitution of antithrombin-III.

Clinically, DIC in malignancy has a less fulminant course than the types of DIC in sepsis and trauma. Particularly, solid tumors are the most common cause of chronic DIC. However, our case was unusual because of its acute presentation of severe DIC which was very difficult to control. The coagulopathy may be triggered by direct surgical manipulation of the tumor. By surgical trauma to the tumor blood vessels, exposure of the subendothelial TF causes the release of cytokines with their procoagulant activity. This can lead to the complication of acute DIC after the trauma to malignant cells910).

In our case, early administration of chemotherapy and vigorous supportive care, including repeated transfusions, controlled the massive bleeding and DIC at the initial diagnosis. In conclusion, for the patients with rhabdomyosarcoma complicated with DIC, the early start of systemic chemotherapy to diminish the malignancy triggered procoagulant activity is important.

Article information Continued